Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq.ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.
For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com
Shared 1 day ago
13 views
Shared 1 month ago
47 views
Shared 3 months ago
92 views
Shared 3 months ago
21 views
Shared 8 months ago
230 views
Shared 8 months ago
70 views
Shared 10 months ago
123 views
Shared 1 year ago
345 views
Shared 1 year ago
438 views
Shared 1 year ago
196 views
Shared 2 years ago
3.6K views
Shared 2 years ago
759 views
Shared 2 years ago
342 views
Shared 2 years ago
261 views
Shared 2 years ago
353 views
Shared 2 years ago
492 views
Shared 2 years ago
449 views
Shared 2 years ago
269 views
Ensure regulatory-grade Safety profile of your lead compound | In Vitro & Genetic Toxicology #shorts
Shared 2 years ago
183 views
Shared 2 years ago
101K views
Shared 2 years ago
432 views
Shared 3 years ago
873 views
Shared 3 years ago
271 views
Shared 3 years ago
1.4K views
Shared 3 years ago
2.6K views
Shared 3 years ago
518 views
Shared 3 years ago
165 views
Shared 3 years ago
569 views
Shared 3 years ago
820 views